Nobuaki Yasuo

Dr. Nobuaki Yasuo

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2019 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
NYNobuaki Yasuo
Nobuaki Yasuo
MSMasakazu Sekijima
Masakazu Sekijima
Virtual screening is a promising method for obtaining novel hit compounds in drug discovery. It aims to enrich potentially active compounds from large chemical library for further biological experiments. However, the accuracy of current virtual screening methods is insufficient. In this study, we develop a new virtual screening method named Similarity of Interaction Energy VEctor Score (SIEVE-Score), in which proteinligand interaction energies are extracted to represent of docking poses for machine learning. SIEVE-Score offers substantial improvements compared to other state-of-theart virtual screening methods, namely, other machine-learning-based scoring functions, interaction fingerprints, and docking software, for the enrichment factor 1% results on the Directory of Useful Decoys, Enhanced (DUD-E). The screening results are also human-interpretable in the form of important interactions for distinguishing between active and inactive compounds. The source code is available at: https://github.com/ sekijima-lab/SIEVE-Score.

1 January 2018 in Journal of Molecular Graphics and Modelling
Verified
Journal Article
Open access
NWNaoki Wakui
Naoki Wakui
RYRyunosuke Yoshino
Ryunosuke Yoshino
NYNobuaki Yasuo
Nobuaki Yasuo
Masahito OhueMasahito Ohue
Masahito Ohue
MSMasakazu Sekijima
Masakazu Sekijima
B-cell lymphoma 2 (Bcl-2) family proteins are potential drug targets in cancer and have a relatively flat and flexible binding site. ABT-199 is one of the most promising selective Bcl-2 inhibitors, and A-1155463 selectively inhibits Bcl-XL. Although the amino acid sequences of the binding sites of these two inhibitors are similar, the inhibitors selectively bind the target protein. In order to determine the origin of the selectivity of these inhibitors, we conducted molecular dynamics simulations using protein-inhibitor modeling. We confirmed that ASP103 of Bcl-2 is a key residue and that hydrogen bonding between ASP103 and ABT-199 confers the Bcl-2 selectivity of this inhibitor. For Bcl-XL selectivity, the secondary structure of α-helix 3 is a key factor. PHE105, SER106, and LEU108 in the loose α-helix 3 interact with A-1155463 to confer Bcl-XL selectivity. These findings provide important insights into the molecular mechanisms of selective inhibitors of Bcl-2 family proteins.

27 November 2021 in Journal of Cheminformatics
Verified
Journal Article
Open access
PDF file
DEDaiki Erikawa
Daiki Erikawa
NYNobuaki Yasuo
Nobuaki Yasuo
MSMasakazu Sekijima
Masakazu Sekijima
The hit-to-lead process makes the physicochemical properties of the hit molecules that show the desired type of activity obtained in the screening assay more drug-like. Deep learning-based molecular generative models are expected to contribute to the hit-to-lead process. The simplified molecular input line entry system (SMILES), which is a string of alphanumeric characters representing the chemical structure of a molecule, is one of the most commonly used representations of molecules, and molecular generative models based on SMILES have achieved significant success. However, in contrast to molecular graphs, during the process of generation, SMILES are not considered as valid SMILES. Further, it is quite difficult to generate molecules starting from a certain molecule, thus making it difficult to apply SMILES to the hit-to-lead process. In this study, we have developed a SMILES-based generative model that can be generated starting from a certain molecule. This method generates partial SMILES and inserts it into the original SMILES using Monte Carlo Tree Search and a Recurrent Neural Network. We validated our method using a molecule dataset obtained from the ZINC database and successfully generated molecules that were both well optimized for the objectives of the quantitative estimate of drug-likeness (QED) and penalized octanol-water partition coefficient (PLogP) optimization. The source code is available at https://github.com/sekijima-lab/mermaid.

11 January 2022 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
KYKazuki Z. Yamamoto
Kazuki Z. Yamamoto
NYNobuaki Yasuo
Nobuaki Yasuo
MSMasakazu Sekijima
Masakazu Sekijima
In addition to vaccines, antiviral drugs are essential for suppressing COVID-19. Although several inhibitor candidates were reported for SARS-CoV-2 main protease, most are highly polar peptidomimetics with poor oral bioavailability and cell membrane permeability. Here, we conducted structure-based virtual screening and in vitro assays to obtain hit compounds belonging to a new chemical space, excluding peptidyl secondary amides. In total, 180 compounds were subjected to the primary assay at 20 μM, and nine compounds with inhibition rates of >5% were obtained. The IC50 of six compounds was determined in dose–response experiments, with the values on the order of 10–4 M. Although nitro groups were enriched in the substructure of the hit compounds, they did not significantly contribute to the binding interaction in the predicted docking poses. Physicochemical properties prediction showed good oral absorption. These new scaffolds are promising candidates for future optimization.

19 December 2024 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
MSMasami Sako
Masami Sako
NYNobuaki Yasuo
Nobuaki Yasuo
MSMasakazu Sekijima
Masakazu Sekijima
The design of drug molecules is a critical stage in the drug discovery process. The structure-based drug design has long played an important role in efficient development. Significant progress has been made in recent years in the generation of 3D molecules via deep generation models. However, while many existing models have succeeded in incorporating structural information on target proteins, they have not been able to address important interactions between protein and drug molecules, especially hydrogen bonds. In this study, we propose DiffInt as a novel structure-based approach that explicitly addresses interactions. The model naturally incorporates hydrogen bonds between protein and ligand molecules by treating them as pseudoparticles. The experimental results show that DiffInt reproduces hydrogen bonds, and the hydrogen binding energies significantly outperform those of existing models. To facilitate the use of our tool for generating new drug molecules based on any protein's three-dimensional structure, we have made the source code and trained model available on GitHub (https://github.com/sekijima-lab/DiffInt) under the MIT license, with the execution environment provided on Google Colab.

25 September 2024 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
TSTakamasa Suzuki
Takamasa Suzuki
DMDian Ma
Dian Ma
NYNobuaki Yasuo
Nobuaki Yasuo
MSMasakazu Sekijima
Masakazu Sekijima
In the field of drug discovery, identifying compounds that satisfy multiple criteria, such as target protein affinity, pharmacokinetics, and membrane permeability, is challenging because of the vast chemical space. Until now, multiobjective optimization via generative models has often involved linear combinations of different reward functions. Linear combinations solve multiobjective optimization problems by turning multiobjective optimization into a single-objective task and causing problems with weighting for each objective. Herein, we propose a scalable multiobjective molecular generative model developed using deep learning techniques. This model integrates the capabilities of recurrent neural networks for molecular generation and Pareto multiobjective Monte Carlo tree search to determine the optimal search direction. Through this integration, our model can generate compounds using enhanced evaluation functions that include important aspects like target protein affinity, drug similarity, and toxicity. The proposed model addresses the limitations of previous linear combination methods, and its effectiveness is demonstrated via extensive experimentation. The improvements achieved in the evaluation metrics underscore the potential utility of our approach toward drug discovery applications. In addition, we provide the source code for our model such that researchers can easily access and use our framework in their own investigations. The source code and pretrained model for Mothra, developed in this study, along with the Docker image for the Pareto front explorer and compound picker, designed to streamline the selection and visualization of optimal chemical compounds, are released under the GNU General Public License v3.0 and available at https://github.com/sekijima-lab/Mothra.